Amgen Deutschland

Amgen Deutschland is a global, independent biotechnology company that was founded in 1980 and is now present in nearly 100 countries with around 27,000 employees. With a focus on utilizing biotechnology to treat severe diseases, Amgen has over four decades of experience in researching, developing, and producing innovative human therapeutics. The company's portfolio includes treatments in nephrology, cardiology, hematology, oncology, bone health, and chronic inflammatory diseases. In addition to original drugs, Amgen also offers biosimilars. In Germany, Amgen operates at two locations with approximately 650 employees. The Amgen GmbH in Munich, established in 1989, primarily focuses on clinical research, drug approval, and distribution, with around 500 employees. Amgen Research (Munich) GmbH, the company's largest research site outside the USA, specializes in innovative cancer therapies and has approximately 150 employees dedicated to the research and development of BiTE® (Bispecific T-cell Engager) molecules. Amgen in Deutschland is dedicated to helping patients, with millions of individuals worldwide benefiting from their therapies annually. The company's commitment to patient care is evident from its mission of utilizing biotechnology to address diseases with limited or no treatment options. For individuals interested in joining the team, Amgen provides information on current job opportunities through its applicant portal for both the Amgen GmbH and the Amgen Research (Munich) GmbH. The company also shares its social media guidelines as well as necessary legal disclaimers related to Amgen's operations in Germany. By leveraging its expertise in biotechnology and research, Amgen Deutschland demonstrates a strong dedication to its mission of providing innovative therapies for patients in need.